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Abstract
Background: Vancomycin resistant enterococcus (VRE) is a major cause of nosocomial infections in the United States
and may be associated with greater morbidity, mortality, and healthcare costs than vancomycin-susceptible
enterococcus. Current guidelines for the control of VRE include prudent use of vancomycin. While vancomycin exposure
appears to be a risk factor for VRE acquisition in individual patients, the effect of vancomycin usage at the population
level is not known. We conducted a systematic review to determine the impact of reducing vancomycin use through
prescribing interventions on the prevalence and incidence of VRE colonization and infection in hospitals within the United
States.
Methods: To identify relevant studies, we searched three electronic databases, and hand searched selected journals.
Thirteen studies from 12 articles met our inclusion criteria. Data were extracted and summarized for study setting,
design, patient characteristics, types of intervention(s), and outcome measures. The relative risk, 95% confidence interval,
and p-value associated with change in VRE acquisition pre- and post-vancomycin prescription interventions were
calculated and compared. Heterogeneity in study results was formally explored by stratified analysis.
Results:  No randomized clinical trials on this topic were found. Each of the 13 included studies used a quasi-
experimental design of low hierarchy. Seven of the 13 studies reported statistically significant reductions in VRE
acquisition following interventions, three studies reported no significant change, and three studies reported increases in
VRE acquisition, one of which reported statistical significance. Results ranged from a reduction of 82.5% to an increase
of 475%. Studies of specific wards, which included sicker patients, were more likely to report positive results than studies
of an entire hospital including general inpatients (Fisher's exact test 0.029). The type of intervention, endemicity status,
type of study design, and the duration of intervention were not found to significantly modify the results. Among the six
studies that implemented vancomycin reduction strategies as the sole intervention, two of six (33%) found a significant
reduction in VRE colonization and/or infection. In contrast, among studies implementing additional VRE control
measures, five of seven (71%) reported a significant reduction.
Conclusion:  It was not possible to conclusively determine a potential role for vancomycin usage reductions in
controlling VRE colonization and infection in hospitals in the United States. The effectiveness of such interventions and
their sustainability remains poorly defined because of the heterogeneity and quality of studies. Future research using high-
quality study designs and implementing vancomycin as the sole intervention are needed to answer this question.
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Background
Since emerging 20 years ago [1], vancomycin-resistant
enterococcus (VRE) has spread throughout the world to
become a major cause of nosocomial infections.  Ameri-
can hospitals have experienced a particularly dramatic
increase in the occurrence of VRE colonization and infec-
tion [2]. According to the Center for Disease Control and
Prevention (CDC), the percentage of enterococcal isolates
resistant to vancomycin reported by United States (US)
hospitals increased from 0.3% in 1989 to over 25% of all
isolates in 1999 [2]. Data from the 2004 National Noso-
comial Infection Survey indicated that VRE caused
approximately one third of infections in intensive care
units (ICUs).
The reported increases in VRE colonization and infection
among hospitalized patients are of concern for several rea-
sons. Infections due to VRE may be associated with greater
morbidity, mortality, lengths of stay and hospital costs
than those due to vancomycin-susceptible enterococci
(VSE), independent of co-morbid conditions that may
have led to infection [3,4]. Of note, this topic remains
controversial as some investigators have reported a lack of
association between VRE infections and increased mor-
bidity and mortality [5-11].
The progression of VRE colonization and infection at an
institution is often from sporadic cases to monoclonal
outbreaks and then to polyclonal endemicity. Once estab-
lished, endemicity is difficult to eradicate [12-14]. Due to
the combination of intrinsic and acquired resistance,
treatment options for infections caused by VRE are
extremely limited. Transfer of vancomycin resistance
determinants to more virulent organisms is also of great
concern, and vancomycin-intermediate and vancomycin-
resistant Staphylococcus aureus have already emerged [15].
In 1995, as a response to rising rates of VRE colonization
and infection, the CDC's Hospital Infection Control Prac-
tices Advisory Committee (HICPAC) established guide-
lines for control of VRE. These include prudent
vancomycin use, as well as infection control measures to
limit cross-contamination. Despite these recommenda-
tions, the precise association between vancomycin use
and VRE colonization and infection remains unclear. Sub-
stantial research from animal models [1,16,17] and indi-
vidual-level studies [18-20] has supported a role of
vancomycin use in contributing to VRE acquisition. In a
meta-analysis by Carmeli et al., among 15 individual-level
studies using optimal control groups, vancomycin expo-
sure conferred a 2.7-fold increased risk of VRE acquisition
[21]. In addition to being a risk factor for VRE acquisition,
vancomycin exposure may also increase VRE detection in
patients already colonized, by eliminating other coloniz-
ing bacteria and allowing VRE to flourish [22].
There are conflicting data, however, that suggest that ante-
cedent vancomycin exposure may not pose significant risk
to individual patients [22-24]. In fact, a review by Har-
barth et al. on antibiotic exposure and VRE concluded that
intravenous vancomycin use may have a limited role in
contributing to new VRE acquisition, while cepha-
losporins and anti-anaerobic agents may have a greater
effect.
Even less clear is the role of vancomycin restriction and
control on clinically significant VRE acquisition at the
population level. Data from the largest ecologic study to
date showed that vancomycin was the most significant
'modifiable' risk factor leading to VRE colonization [25].
Yet results from studies investigating the impact of reduc-
tions in vancomycin use on VRE colonization and infec-
tion have been heterogeneous [20,26-36]. We conducted
a systematic review of the available literature to evaluate
the impact of reducing vancomycin use through vancomy-
cin prescribing interventions on the prevalence and inci-
dence of VRE colonization and infection in US hospitals.
Methods
Search strategy
We searched the following electronic databases: PubMed
including Medline, as well as Web of Science, and the
Cochrane Library. Searches were limited to studies pub-
lished from 1987 (the year VRE was first reported in the
US) to March 2006 (the date the search was conducted);
searches were also limited to human subjects. The search
terms included "Enterococcus," "Enterococcus faecalis,"
"Enterococcus faecium," "vancomycin," "antibiotic resist-
ance," "antimicrobial resistance," "drug resistance," "pre-
scribing," "guidelines," "restriction," "colonization," and
"infection." All titles and abstracts (if available) from each
of the searches were examined, with relevant articles being
obtained for review. In articles with unclear relevance, full
text versions were also scanned. Subsequently, reference
lists of all identified reports, studies and reviews were
screened to identify additional studies. Although we did
not impose language restriction while searching, we
included only English language articles in our review.
Selection criteria
Inclusion criteria were established before identifying arti-
cles to avoid selection bias. Eligible studies were experi-
mental in design (randomized controlled trials or quasi-
experimental studies), conducted within US hospitals,
and described the impact of significant reductions in van-
comycin use, following any intervention(s) aiming to
reduce its use, on the prevalence or incidence of VRE.
Measurements of VRE acquisition (colonization or infec-
tion) within a control group not exposed to the interven-
tion were required for comparison, although noBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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minimum number of data points was imposed. Only
published studies were included.
We excluded the following: studies outside of the United
States (since the epidemiology of VRE is different else-
where), animal studies, reviews, case reports and observa-
tional studies. Also excluded were studies that did not
observe a significant reduction in vancomycin use follow-
ing an intervention aimed at doing so since this was the
intervention of interest. Finally, we excluded studies with
a focus on antecedent vancomycin use as a risk factor for
VRE acquisition in individual patients, as this review
focused on population level associations. The review
could not be limited to studies investigating the effect of
vancomycin use reductions alone on VRE colonization
and infection, as several studies simultaneously investi-
gated other interventions, such as restriction of other anti-
biotics and infection control measures. If a trial had
multiple published reports, the latest reports, with the
longest duration of follow up, were included. No studies
were excluded based on quality criteria alone.
Data extraction and outcome measures
The final set of included articles was assessed by one
reviewer (MAD), who extracted data from all studies. The
reviewer was not blinded to the names of the authors,
institutions, journal of publication or study results. Infor-
mation was collected on the publication year, study
period, setting, design, number of participants, selection
and characteristics of participants, laboratory methods for
determination of VRE infection status, characteristics and
timing of interventions, duration of follow-up, timing
and frequency of outcome measurements, and the report-
ing of other possible confounding variables.
The outcome measures of interest were extracted from
each study. These included measurements of vancomycin
use and prevalence or incidence of VRE acquisition before
and after an intervention to reduce vancomycin usage,
and the corresponding confidence intervals (95%) when
provided. Data from the entire pre- and post-intervention
periods, or as much as reported, were included. When sev-
eral months or years of pre- and post-intervention data
were reported separately, the data for each period was
combined. For example, data reported as the incidence of
cases in each individual month were combined to find the
cases per day over all months in the time period, assuming
30 days per month. For studies in which an intervention
took place during a certain month, the prior month(s)
were included as pre-intervention and following
month(s) as post-intervention, but the actual month of
intervention was excluded from these periods.
Data analysis and statistical methods
Absolute and relative (percentage) changes in vancomy-
cin use and VRE acquisition were calculated from pre- and
post-intervention data. The relative risk (RR) of VRE colo-
nization or infection in the intervention group compared
with the control group was calculated by dividing the
probability of VRE acquisition in the post-intervention
period by the probability of VRE acquisition in the pre-
intervention period. A RR below one represented a protec-
tive effect of vancomycin reduction on VRE colonization
or infection. When sufficient data were reported, the 95%
confidence interval for the RR and the p-value were calcu-
lated by EpiInfo StatCalc. Statistical significance was indi-
cated by a p-value of less than 0.05. For studies reporting
cases per unit of time without including the number of
patients tested, it was assumed that the number of
patients tested per unit of time was constant. When sam-
ple size was reported in terms of the number of cultures
over the entire study period, it was assumed that a con-
stant number of cultures were obtained for each unit of
time, in order to obtain the sample size for pre- and post-
intervention periods, and thereby permit calculation of
the confidence intervals for relative risk.
Studies were categorized according to the hierarchy of
quasi-experimental study designs [37]. According to this
classification scheme, category A studies do not use con-
trol groups, while category B studies do. A1 studies use a
1-group pretest-posttest design and A2 studies use a 1-
group pretest-posttest design with a double pretest. We
have chosen to denote A1 studies which use multiple
posttest measurements as "A1*" and A2 studies using
multiple posttest measurements as "A2†." In general, stud-
ies using a control group are of higher quality than those
without controls, and studies with multiple pretest and
posttest measurements are preferable to those without
such repeated measurements. For a more complete review
on the subject, see bibliographical reference 36.
Because of the heterogeneity among study designs, popu-
lations, interventions, and quality, a pooled summary
estimate would not provide a meaningful estimate of
effect; therefore, meta-analysis was not performed.
Instead, a simple vote count was tabulated to determine
the number of studies finding a significant decrease,
increase or no change in prevalence or incidence of VRE
colonization and/or infection. The range of point esti-
mates for each category of studies was noted.
To explore heterogeneity, we stratified studies by pre-spec-
ified covariates, each having clinical rationale, to investi-
gate possible effect modification. Covariates included 1)
vancomycin reduction alone vs. concomitant implemen-
tation of other VRE control interventions, 2) ward-specific
vs. hospital-wide interventions, 3) severity of illness of theBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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study population, 4) outbreak status of the institution or
ward(s) under investigation, 5) type of quasi-experimen-
tal design and 6) duration of intervention.
The proportion of studies in each stratum finding an
increase, decrease and no change in VRE colonization
and/or infection, and the range of point estimates within
each stratum was noted. The quality of each study was
assessed by informal methodological criteria, and possi-
ble sources of bias were investigated. Discrepancies in
study quality were examined as potential contributors to
inter-study heterogeneity.
Results
Search results
Of the 2027 citations identified after literature searches,
12 were judged to meet our inclusion criteria and were
included in this review [20,26-36]. All included studies
presented pre- and post-intervention data, with the preva-
lence or incidence of VRE colonization and/or infection
compared before and after implementation of a vancomy-
cin use reduction intervention at the institution or ward
under investigation. No similar systematic reviews or ran-
domized controlled trials were found.
Description of included studies
Table 1 describes the major characteristics of each study
included in the review. A total of 12 articles describing 13
studies are included. The studies were published between
1992 and 2005. They were clustered around the lowest
ranking designs of the classification of quasi-experimental
studies proposed by Harris et al. [37] (Table 1). All studies
lacked a control group and none removed and reintro-
duced interventions. Eleven of 13 took place at a single
teaching hospital [20,26-29,31-33,35,36], one was at a
non-teaching community hospital [30] and one was a
multi-center trial of both academic and community hos-
pitals [34]. One study reported initial cases of VRE coloni-
zation [26], two reported current outbreaks without an
endemic problem [27,28], and one reported a superim-
posed outbreak on an endemic problem with VRE infec-
tions [31]. Aside from the multi-site study that did not
specify outbreak status [34], the remaining studies
described a VRE problem of several years duration
[20,26,29,30,32,33,35,36]. No article provided explicit
definitions for outbreak vs. endemicity, and classifica-
tions may have varied. One study reporting an outbreak
described it as lasting over four years [27]; it is possible
that other studies may have considered this type of time
frame to constitute endemicity.
Six studies implemented institution-wide interventions to
a population of general inpatients [20,27,29,30,35,36],
while seven performed ward-specific interventions
including malignant hematology [33], oncology [26,32],
ICU [26,31,34,36] or "high-risk" [28] patients. For all
studies, the comparison group consisted of patients in the
same hospital or ward as the intervention group, but prior
to the implementation of the intervention. Therefore, the
two groups differed temporally. Few studies provided
comparison of key features of the two groups, including
type and severity of illness, length of stay, and other fea-
tures known to affect the risk of VRE acquisition. The types
of interventions, and the timing and sequence of imple-
mentation varied widely. Six studies implemented vanco-
mycin reduction efforts alone [29,30,34-36], five
implemented vancomycin reduction efforts plus infection
control [20,26,28,31,33], and the remaining studies used
a combination of vancomycin reduction efforts, infection
control efforts, and efforts to reduce the use of other
classes of antibiotics [27,32,35]. All studies conducted
during outbreaks [27,28,31] involved multiple interven-
tions simultaneously, presumably due to the urgency of
controlling the outbreak. Studies used several different
measures and units for tracking changes in vancomycin
use.
Measures of VRE included colonization and/or infection,
with studies varying on which they used, whether they
provided definitions for their measure(s), and if provided,
which definitions they used. Two studies reported meas-
uring colonization only [20,26]. One study reported
measuring the percentage of VRE in surveillance cultures
of high risk patients, and it is unclear whether this number
represents colonization with or without infection [28].
Three studies reported the proportion of enterococcal iso-
lates resistant to vancomycin among specimens ordered
for clinical reasons [29,34,35], and the study by Morgan
et al. states explicitly that this number represents both col-
onization and infection [29]. Three studies reported colo-
nization and infection separately [27,32,33]. All
definitions of colonization were similar, defined as the
proportion of surveillance cultures or proportion of a
point prevalence survey that were VRE-positive. Three
studies reported infections without providing definitions
[30,36] and two stated using the CDC definition of infec-
tion [32,33].
Studies used various sampling methods to detect cases of
VRE acquisition, including testing all patients in a study
population at a given time [26,33], obtaining random
samples of study participants and screening for VRE
[20,27], sampling patients thought to be at high risk of
VRE acquisition [28,31], and obtaining clinical isolates
[29,30,34-36]. As such, sample size varied from a rela-
tively small sample of the inpatient census at a given time
to the entire patient census at a given time, to all patients
admitted to a hospital over several years. Measures of dis-
ease occurrence included serial point prevalence surveys
or determination of incidence, which involved evaluatingBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
Page 5 of 11
(page number not for citation purposes)
the number of new cases over time or patient-days. The
duration of follow up ranged from four months to eight
years, with a median duration of 23 months and a mean
duration of 27 months. Little or no data were reported on
the following characteristics of study participants: age,
gender, or underlying illnesses including HIV.
Overall impact of vancomycin reductions on VRE 
acquisition
Table 2 describes the relative reduction in vancomycin use
and changes in VRE acquisition for each of the studies. All
articles, by definition of inclusion, reported a significant
reduction in vancomycin use. The study by Lai et al. [31]
reports initial unsuccessful attempts to reduce vancomy-
cin use, followed by vancomycin restriction efforts which
were successful. Our analysis of this study includes only
the portion in which vancomycin was restricted, during
which time vancomycin usage was significantly reduced.
The study by Lautenbach et al. [35] reports an initial sig-
nificant reduction in vancomycin usage, but then usage
returned to pre-intervention levels by the end of the study.
In this case, we included only the initial period during
which vancomycin use was significantly reduced, as the
latter portion did not meet inclusion criteria. The multi-
Table 1: Characteristics of studies included in the systematic review
Study Setting Study 
population
VRE at 
institution
Study design Intervention(s) Length of 
follow up
Vancomycin use 
outcome
VRE outcome
[26] Children's hospital Pediatric 
oncology and 
ICU
Initial cases A2† VR + IC 5 mos. Proportion of patients 
receiving
Prevalence of 
colonization
[20] Academic hospital General 
inpatient
Endemic A2† IC → VR 6 mos. PO and IV doses/mo. Prevalence of 
colonization
[27] VA hospital General 
inpatient
Outbreak 1)A1 2)A2† IC→ restrict 
vanco, 
ceftazidime and 
clindamycin
6 mos. PO and IV units/mo. Prevalence of 
colonization, incidence 
of positive clinical 
isolates
[28] Academic hospital "High risk ward" Outbreak A1* VR + IC 4 mos. % of orders 
inappropriate per 
HICPAC, grams/1,000 
pt-days
Incidence of positive 
surveillance cultures
[29] Academic hospital General 
inpatient
Endemic A1 VR 24 mos. Grams/1,000 pt-days, 
total # of patients 
exposed
Incidence as % of all 
enterococcal isolates 
resistant to vanco
[30] Non-teaching 
community hospital
General 
inpatient
Endemic A2† Vanco education 
program → VR
24 mos. Doses purchased/1,000 
pt-days, dollar 
purchases/1,000 pt-
days, empiric 
treatment, treatment 
with positive culture
Incidence of 
colonization or 
infection (quarterly)
[31] ICUs of an academic 
hospital
ICU Endemic with 
super-imposed 
outbreaks
A2† IC + progressive 
VR
19 mos. Doses/1,000 pt-days Incidence of 
colonization and 
infection (monthly)
[32] Academic oncology 
ward
Oncology Endemic A1 IC→ enhanced 
IC (included 
efforts to reduce 
use of all 
antimicrobials) + 
VR
12 mos. Grams/1,000 pt-days Incidence of 
colonization/1,000 pt-
days and BSI/1,000 pt-
days
[33] Academic cancer 
center's BMT and 
leukemia ward
Heme 
malignancy
Endemic A1* VR + IC 36 mos. Empiric use in grams/
1,000 pt-days Cost/
1,000 pt-days
Incidence of total 
infections/1,000 pt-
days and BSI/1,000 pt-
days
[34] 50 ICU's at 20 
hospitals; academic, 
VA and community
ICU Not reported A1 Vanco use local 
monitoring data 
compared with 
national 
benchmarks
23 mos. DDD/1,000 pt-days Prevalence of positive 
clinical isolates
[35] Academic hospital General 
inpatient
Endemic A1* Progressive VR 4 yrs. DDD/1,000 pt-days Prevalence as annual % 
of enterococcal 
isolates resistant to 
vanco
[36] Academic hospital General 
inpatient
Endemic A1 VR 8 yrs % of orders 
inappropriate per 
HICPAC guidelines; 
grams/1,000 pt-days
Incidence: infections/yr
[36] ICU ICU Endemic A1* Multidisciplinary 
ICU team to 
reduce vanco use
4 yrs. % of orders 
inappropriate per 
HICPAC guidelines
Incidence: infections/yr, 
infections/1,000 pt-
days
Abbreviations: ICU = intensive care unit, BMT = bone marrow transplant, VA = Veteran's Affairs, → = followed by, DDD = defined daily dose, 
HICPAC = Hospital Infection Control Practices Advisory Committee, Pt-days = patient-days, BSI = blood stream infections, VR = vancomycin 
restriction, IC = infection control, vanco = vancomycin
Footnotes: A1 = 1-group pretest-posttest design; A2 = 1-group pretest-posttest design that uses a double pre-test (for a complete description of 
hierarchy of quasi-experimental design studies, see Harris et al.), * Category A1 with multiple post-tests;† Category A2 with multiple post-testsBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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center trial by Fridkin et al. describes reductions in vanco-
mycin use for sites implementing unit-specific interven-
tions but not for those implementing hospital-wide
interventions; only data from sites with unit-specific inter-
ventions were included [34]. The article by Guglielmo et
al. includes a hospital-wide intervention to reduce vanco-
mycin use and corresponding changes in VRE infections,
as well as a later ICU-specific intervention, again with cor-
responding changes in VRE infections [36]. Since the
results of these two interventions are reported separately
in their article, they are discussed as separate studies in
this review, and count as separate votes in the stratified
analysis.
Overall, the 13 studies reported inconsistent findings.
Seven studies [26-28], [32-34,36] reported statistically sig-
nificant improvement in the prevalence or incidence of
VRE colonization and/or infection, with relative reduc-
tions ranging from 46% [33] to 82.5% [26]. Three studies
reported no change in levels of VRE colonization [20,30]
or clinical isolates [29]. Three studies reported an increase
in VRE measures, one of which was statistically significant
[35]. The other two noted increases of 33.5% [31] and
475% [36], but with no indication of significance and
with insufficient data reported to calculate the p-value.
Stratified analysis
As described above, substantial heterogeneity was present
in the direction and magnitude of study outcomes, likely
reflecting the widely varying study settings, populations,
and interventions. To explore this heterogeneity, we strat-
ified by pre-specified covariates suspected of affecting the
Table 2: Study results – reductions in vancomycin use and changes in VRE
Reference Vancomycin use % 
reduction
VRE acquisition 
absolute change
VRE acquisition 
percentage change
Significant change in 
VRE acquisition?
RR of VRE after 
intervention(s)
(95% CI)
Rubin et al [26], 1992 66% -.157 proportion of 
patients colonized 
(prevalence)
-82.5% p = 0.023 (FET) 0.17 (0.04, 0.72)
Morris et al [20], 1995 66% -0% mean rate of stool 
colonization (prevalence)
0% NS 0.96 (0.59, 1.57)
Quale et al [27], 1996a 44% -32% point prevalence of 
fecal colonization
-2.1 new patients with 
positive cultures per 
month (incidence)
-68% (prevalence)
-39% (incidence)
p < 0.001 (prevalence)
p = 0.03 (incidence)
0.32 (0.22, 0.46) 
(prevalence)
* (incidence)
Anglim et al [28], 1997 47% -0.52 cases/day (incidence) -52.2% Chi-square test for trend, 
16.6; p = 0.002
0.48 (0.31, 0.75)
Morgan et al [29], 1997 9% -0% of all enterococcal 
isolates resistant to 
vancomycin (incidence)
0% NS 1 (*)
Adachi et al [30], 1997 54% "No further increase" 
(incidence)
~0% NS 1.75 (*)
Lai et al [31], 1998b 25% +2.46 cases/month 
(incidence)
+33.5% * 1.33 (*)
Montecalvo et al [42], 
1999
28% -10.4 pts/1,000 pt-days 
(colonization)
-1.65 pts/1,000 pt-days 
(BSI) (incidence)
-50% (colonization)
-79% (BSI)
p < 0.001 (colonization)
p = 0.04 (BSI)
0.5 (0.33, 0.75) 
(colonization)
0.22 (0.05, 0.92) (BSI)
Shaikh et al [33], 2002 50% (g/1,000 pt-days)
53% ($/1,000 pt-days)
-0.21 cases/1,000 pt-days 
(total incidence)
-0.157/1,000 pt-days (BSI) 
(incidence)
-48% (total incidence)
-46% (BSI)
p = 0.008 (total infections)
p = 0.027 (BSI)
0.52* (total incidence)
0.54* (BSI)
Fridkin et al [34], 2002c 35–37% median difference -7.5% mean difference in 
prevalence
Unable to calculate with 
provided data
"Statistical significance" * *
Lautenbach et al. [35], 
2001d
Period 3 vs. 1: 26.3%
Period 2 vs. 1: 8.1%
Period 3 vs. 2: 19.8%
% of enterococcal isolates 
resistant to vancomycin 
(prevalence):
Period 3 vs. 1: +9.5%
Period 2 vs. 1: +7.6%
Period 3 vs. 2: +1.9%
Period 3 vs. 1: +54.6%
Period 2 vs. 1: +43.7%
Period 3 vs. 2: +7.6%
p < 0.001 (detected with 
χ2 test for trend)
Period 3 vs. 1: 1.55 (1.37, 
1.74)
Period 2 vs. 1: 1.44 (1.27, 
1.62)
Period 3 vs. 2: 1.076 
(0.968, 1.195)
Guglielmo et al. [36] 2005 
(hospital-wide study)
86.7% inappropriate use +7.94 infections/month 
(incidence)
475% * 5.77 (*)
Guglielmo et al. [36] 
(ICU-specific study)
33.4% inappropriate use -1.17 infections/month
-4.1 infections/1,000 pt 
days (incidence)
-48% (infections/month), -
65.1% (infections/1,000 pt 
days)
p = 0.0003 (infections/
1,000pt-days)
0.517 (infections/month), 
0.35 (0.22, 0.57) 
(infections/1,000 pt days)
Abbreviations: FET = Fisher's exact test, NS = not significant, BSI = blood stream infection
*Insufficient data reported to perform calculation
aQuale: only prevalence data used to calculate significance, RR (CI); insufficient data to calculate for incidence
bLai: data on VRE incidence are from five months prior to intervention and final five months of follow up
cFridkin: includes only data from ICUs implementing unit-specific change
dLautenbach: table includes data from initial three of four study periods; following are data from the fourth period compared with the first: increase 
in vancomycin use of 15.5%, VRE absolute change +6% of enterococcal isolates resistant to vancomycin, VRE acquisition % change +66.7%, 
significant increase with p < 0.001, RR = 1.70 (1.53, 1.89)BMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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study results, and performed simple vote counts of the
number of studies within each strata (Table 3).
Six studies (46%) implemented vancomycin reduction
measures as the sole type of VRE control intervention
[29,30,34-36]. The remaining seven studies also imple-
mented infection control and/or restriction of additional
antimicrobial agents [20,26-28,31-33]. Although it was
not statistically significant, studies that controlled vanco-
mycin alone revealed a trend towards lower efficacy in
reducing VRE colonization and infection (33%) when
compared to those that used additional measures (71%).
Additionally, both studies (100%) restricting multiple
classes of antimicrobial agents reported improvements
[27,32].
We investigated whether results of studies varied by ward-
specific vs. hospital-wide interventions and by severely ill
vs. moderately ill patient populations. Both stratifications
yielded identical results, as all ward-specific units
included sicker patients. Six of seven studies (86%) focus-
ing on ward-specific interventions and including severely
ill patients reported significant reductions in VRE coloni-
zation and/or infection [26,28,32-34,36]; only one did
not [31]. Of the studies implementing hospital-wide VRE
control efforts and including moderately ill patients, only
one [27] of the six [20,27,29,30,35,36] (17%) reported a
reduction in VRE colonization or infection during the
post-intervention period. Fisher's exact test comparing the
strata yielded a p-value of 0.029. Two of the articles
describe implementation of both unit-specific and hospi-
tal-wide interventions, and assessed the impact of each on
VRE colonization and/or infection separately [34,36].
Both of these (100%) reported reductions in VRE infec-
tions for the ICU-specific interventions, but worsening of
VRE infections for the hospital-wide interventions, with
one also failing to reduce vancomycin use at the hospital
level. This example may highlight the relative success of
interventions implemented at the ward-level compared
with the hospital-level.
Study results were suspected of varying by whether an
institution was facing an outbreak and/or endemic prob-
lem with VRE. Outbreaks tend to be easier to control than
endemic problems. Further, by definition, outbreaks are
recognized as such when they are controlled [12,13,38].
All three studies (100%) at institutions without endemic
VRE reported reductions in post-intervention VRE acquisi-
tion; two of these were amidst an outbreak [27,28] and
one during the institution's initial cases [26]. The studies
with an endemic VRE problem reported less favorable
results: of the nine [20,26,29-33,35,36], only three (33%)
[32,33,36] reported significant reductions in VRE coloni-
zation or infection and another three (33%) reported no
improvement [20,29,30]. The study with an outbreak
superimposed on an endemic VRE problem reported
worsening of VRE acquisition [31], perhaps suggesting
less success of interventions during an endemic problem,
whether or not super-imposed outbreaks are present. As
noted above, the multi-site study by Fridkin et al. was
excluded from this analysis because it lacked information
regarding outbreak status of the various sites [34].
To assess for an association between study design and
results, we stratified studies according to the hierarchy of
quasi-experimental study designs scheme [37]. Five stud-
Table 3: Stratification by covariates
Variable Number of studies Significant % reduction in VRE acquisition Fisher's exact test comparing strata
Type of intervention NS1
Vancomycin reduction alone 6 2
Vancomycin plus other interventions 7 5
Site-based2 (p = 0.029, FET2)
Ward alone 7 6
Hospital-wide 6 1
VRE acquisition occurrence3 NS
Outbreak only 2 2
Endemic (with or without outbreak) 9 3
Study design NS
A1 5 3
A1* 4 4
A2 † 52
Duration of intervention NS
≤ 6 months 4 3
> 6 months 9 4
1 NS = not significant result of Fisher's exact test comparing strata
2 Stratification by severity of illness yields identical results to the site-based stratification: "ward alone" and "high severity of illness" are identical 
strata; "hospital wide" and moderate severity of illness" are identical strata
3Excluded Rubin et al. (initial cases) and Fridkin et al. (multi-cite, outbreak/endemic status not reported)
A1 = 1-group pretest-posttest design; A2 = 1-group pretest-posttest design that uses a double pre-test (for a complete description of hierarchy of 
quasi-experimental design studies, see Harris et al.), * Category A1 with multiple post-tests; † Category A2 with multiple post-testsBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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ies were of 1-group pretest-posttest design (A1), four were
of this same design but with multiple posttests (A1*), and
five performed a double pretest with multiple posttests
(A2†). No significant difference in outcomes based on the
present small variations in design could be detected, per-
haps due to the small number of studies in each category.
For A1 classification, the proportion of studies finding a
significant reduction in VRE was 3/5 (60%), for A1* stud-
ies, 4/4 (100%), and for A2†studies, 2/5 (40%) (see Table
1 footnote).
Finally, the duration of an intervention was assessed for
its impact on results. Interventions may take time to have
an impact on VRE acquisition, and in turn the efficacy of
interventions may wane over time, particularly since there
is a behavioral component to the types of interventions
employed by studies. Furthermore, the background VRE
epidemiology in the US is one of continued increase, so
studies looking over a longer time period may have
greater difficulty in achieving reductions in VRE. Three
[26-28] of four studies [20,26-28] (75%) with interven-
tions of less than or equal to six months reported signifi-
cant improvement in VRE acquisition. Of note, these four
studies were the earliest performed of all included in this
review. Fewer studies with interventions lasting greater
than six months saw improvement; four [32-34,36] of
nine [29-36] (44%) reported significant reductions in VRE
acquisition. Further, one of these studies [35] with inter-
ventions lasting seven years, reported that after four years,
the interventions were no longer effective and vancomy-
cin usage returned to baseline. Meanwhile, VRE acquisi-
tion increased throughout the study period.
Discussion
Many US hospitals continue to struggle with worsening
rates of VRE colonization and infection, and current
guidelines for prudent vancomycin use are lacking in evi-
dence for their effectiveness [39]. Determining the effect
of this particular VRE control strategy would assist hospi-
tals to better direct their infection control efforts. This
review summarizes the impact of reductions in vancomy-
cin use on VRE colonization and infection at the popula-
tion level, based on a systematic review of the literature.
Principal findings
Our findings indicate that a slight majority of studies
demonstrated improvement in control of the organism
following reductions in vancomycin use, although indi-
vidual studies reported a wide range of results. Seven of
thirteen studies (54%) reported reductions in VRE coloni-
zation and/or infection; three (23%) reported no signifi-
cant change, and three (23%) reported increases. Overall
the percentage change in VRE acquisition ranged from a
reduction of 82.5% [26] to an increase of 475% [36].
Interestingly, of six studies that used vancomycin restric-
tion as the sole intervention, only two showed a signifi-
cant reduction in VRE acquisition, whereas of the seven
that implemented antimicrobial drug restriction plus
infection control, five showed a significant VRE acquisi-
tion reduction. This observation suggests that an effective
intervention for VRE infection and colonization control
may require more than drug restriction alone.
Limitations of this review
Our analysis has significant limitations related to the
methodology and reporting of the available studies. None
of the 13 studies reviewed in this report used experimental
designs that would have allowed a definitive answer to
our main question. Each of these studies used a quasi-
experimental approach of lower hierarchy. In fact, all the
studies fell below category A3 of the classification pro-
posed by Harris et al. [37] (Table 1). Quasi-experimental
studies possess significant limitations including 1) diffi-
culty in controlling for important confounding variables
(due to lack of randomization), 2) results that are
explained by the statistical principle of regression to the
mean (the principle that elevated rates will tend to return
to baseline, even without an intervention) and 3) matura-
tion effects (natural changes over time) [40].
None of these studies used segmented regression analysis
nor were they randomized clinical trials. To evaluate the
efficacy of a single intervention (e.g. reduction in vanco-
mycin usage), randomized clinical trials may be ethically
unacceptable given that commonly there is urgency in
controlling an infectious agent or disease (e.g. VRE colo-
nization and infection) in a timely manner and in includ-
ing other interventions (e.g. infection control, reduction
in the usage of other antibiotics). An alternative to rand-
omized clinical trials may be the use of segmented regres-
sion analysis. This experimental approach is considered
superior in design to other types of quasi-experimental
studies by several investigators [33]. Segmented regression
analysis enhances the internal validity of results, as com-
pared with a simple comparison of composite data from
pre- and post-intervention periods. None of the 13 studies
obtained or provided sufficient data for us to perform a
segmented regression analysis. To perform such analysis
would have required collection of pre- and post-interven-
tion data at equally spaced time intervals that span
enough periods to detect pre-existing trends and cyclical
patterns. Specifically, according to Wagner et al. [41], a
general recommendation is to obtain 12 data points both
before and after the intervention.
Most studies provided no data comparing pre- and post-
intervention groups, which would be helpful since studies
are not randomized. All but two studies were conducted at
a single institution, limiting the generalizeability of
results. Most studies did not adjust vancomycin usageBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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rates for patient-days at risk. Morgan et al. demonstrated
the importance of this adjustment [29]. Based on unad-
justed data, they found a significant reduction in vanco-
mycin usage; however, after adjusting for total patient
days and for the percentage of patients receiving vanco-
mycin, the two groups appeared to be "similar" in terms
of vancomycin usage (no p-value reported). Often concur-
rent interventions were implemented, which likely con-
founded the results. Studies did not assess the influence of
"contact patterns" (i.e. individual contact episodes with
VRE carriers) and "colonization pressure" (the overall
proportion of patients colonized with VRE in the unit),
which are central components of VRE transmission, since
the organism is predominantly spread by cross-contami-
nation.
The heterogeneity of studies and results were of concern,
and prevented us from conducting meta-analysis. Simple
vote counts of individual studies were instead performed;
these methods are crude and do not take into account
sample size or variance, and do not provide a summary
estimate of effect. In performing subgroup analysis by key
variables to explore heterogeneity, the number of studies
in individual strata was small. Therefore, our ability to
detect a significant difference may have been limited by
these small numbers.
Based on sub-group analysis by simple vote counts, results
appeared to vary by the following covariates: type of inter-
vention, ward-specific vs. hospital-wide interventions
(significant p-value), severity of illness of patient popula-
tions (significant p-value), VRE acquisition occurrence at
the institution, study design, and the duration of the inter-
vention. Studies with longer durations of interventions
often reported less successful results. As an example, Lau-
tenbach et al. [35] report that after the fourth year of van-
comycin reduction efforts, vancomycin usage had
increased to baseline, while VRE acquisition continued to
increase throughout the study period. Such findings may
relate to challenges with sustaining interventions, as well
as background increases in the overall prevalence and
incidence of VRE within the United States.
Other possible explanations for the observed heterogene-
ity include variability in study quality, interventions to
reduce vancomycin, study populations and their selec-
tion, differences between interventions and control
groups including non-concurrence, differences in out-
come measures and duration of follow up. For  example,
the setting and design of studies evolved over the 13 years.
Earlier  studies involved initial cases of VRE or outbreaks,
and follow up lasted only  months; in contrast, recent
studies were in endemic settings and follow up  lasted up
to a decade. Lack of control for confounding variables
may also be affecting study results differentially.
In addition to heterogeneity across studies and the pres-
ence of confounding variables, other possible reasons for
the mixed results should be considered. In some studies,
vancomycin usage rates may have been insufficiently
reduced to realize benefit or cross-contamination may
have limited the efficacy of vancomycin reduction inter-
ventions. Alternatively, targeting antibiotic use, including
vancomycin, may not be sufficient to reduce the incidence
of VRE cases in endemic settings, since a significant
number of infected or colonized patients may continue to
serve as reservoirs.
Suggestions for the design of future studies
Several of the methodological shortcomings observed in
the studies reviewed here could be improved upon in
future research. Ideally, randomized clinical trials should
be performed. However, this design is often considered
impractical by infection control personnel and may be
unethical in outbreak settings. Alternatively, implement-
ing higher quality quasi-experimental study designs (e.g.
category B designs, which use control groups) or using
segmented regression analysis may allow for more causal
interpretation of observed associations than using quasi-
experimental designs of lower quality (e.g. less than A3)
[37,40]. When possible, distinct control groups should be
used. Collection of additional data points before and after
implementation of an intervention may shed further light
on baseline trends, the immediate and sustained impacts
of the intervention, maturation effect, and cyclical/sea-
sonal patterns. By having sufficient data points to perform
segmented regression analysis, the internal validity of
studies would be improved.
In order to clearly answer the question of whether reduc-
tion in vancomycin usage results in a decrease of VRE col-
onization and disease, a significant decrease in
vancomycin prescriptions should be the only variable
introduced. This approach would not be possible in out-
break settings. However, it would be feasible in endemic
settings where there is less of a need for concurrent imple-
mentation of infection control measures. Additionally,
collection of adequate pre-intervention data points would
be more possible because of relatively less urgency. More
discussion of why authors chose their particular study
designs, as well as their strengths and limitations would
be helpful to readers and in the design of future studies.
Standardized nomenclature regarding study designs
should be implemented to enhance the clarity of research
designs and methodology.
Conclusion
In summary, based on this systematic review of the litera-
ture, it was not possible to conclusively determine a
potential role for vancomycin usage reductions in control-
ling VRE colonization and infection in hospitals in theBMC Infectious Diseases 2007, 7:24 http://www.biomedcentral.com/1471-2334/7/24
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Untied States, as is recommended by current guidelines
[39]. The effectiveness of such interventions and their sus-
tainability remain poorly defined because of heterogene-
ity in study design and results, as well as insufficient study
quality to enable adequate causal inference. In general,
studies implementing vancomycin reduction as the sole
intervention to control VRE were less successful than
those implementing additional VRE control strategies,
although there may have been too few studies to detect a
significant difference between groups. Future research
using experimental designs of higher quality and imple-
menting vancomycin use reduction as the sole interven-
tion is needed to answer this question.
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